Table 1.
Participant demographics for all participants and for both of the dose sequence groups separately+.
| Measure | Low-Dose-1st (High-Dose-2nd) (n=25) | High-Dose-1st (Low-Dose-2nd) (n=26) | All Participants (n=51) |
|---|---|---|---|
| Gender (% female) | 48% | 50% | 49% |
| Age in years (mean, SEM) | 56.1 (2.3) | 56.5 (1.8) | 56.3 (1.4) |
| Race/Ethnicity | |||
| White | 92% | 96% | 94% |
| Black/African American | 4% | 4% | 4% |
| Asian | 4% | 0% | 2% |
| Education | |||
| High school | 4% | 0% | 2% |
| College | 32% | 58% | 45% |
| Post-graduate | 64% | 42% | 53% |
| Relationship status (married or living with partner) | 72% | 65% | 69% |
| Lifetime use of hallucinogens | |||
| Percent reporting any past use | 56% | 36% | 45% |
| Years since last use (mean, SEM) | 30.9 (3.2) | 30.0 (4.5) | 30.6 (2.6) |
| Recent use of cannabis or dronabiol | |||
| Percent reporting recent use | 52% | 42% | 47% |
| Users use per month (mean, SEM) | 4.7 (1.6) | 7.0 (2.1) | 5.8 (1.3) |
| Cancer prognosis at time of enrollment | |||
| Possibility of recurrence | 32% | 38% | 35% |
| Recurrent/metastatic (>2yr anticipated survival) | 32% | 42% | 37% |
| Recurrent/metastatic (<2yr anticipated survival) | 36% | 19% | 27% |
| Psychiatric symptomsa | |||
| Depressed mood | 72% | 65% | 69% |
| Anxiety | 68% | 58% | 63% |
| Prior use of medication for anxiety or depressionb | 52% | 50% | 51% |
There were no significant differences between the two dose sequence groups on any demographic variable (t-tests and chi-square tests with continuous and categorical variables, respectively).
Psychiatric symptom classification was based on SCID (DSM-IV) diagnoses. All had a DSM-IV diagnosis: chronic adjustment disorder with anxiety (11 participants), chronic adjustment disorder with mixed anxiety and depressed mood (11), dysthymic disorder (5), generalized anxiety disorder (GAD) (5), major depressive disorder (MDD) (14), or a duel diagnosis of GAD and MDD (4), or GAD and dysthymic disorder (1). Depressed mood was defined as meeting criteria for MDD, dysthymic disorder, or adjustment disorder with anxiety and depressed mood, chronic. Anxiety was defined as meeting criteria for GAD, adjustment disorder with anxiety, chronic, or adjustment disorder with anxiety and depressed mood, chronic.
Data in this row refer to percentage of participants who had received antidepressant or anxiolytic medication after the cancer diagnosis but had terminated the medication sometime before study enrollment because they had found it to be unsatisfactory.